ZBIO (Zenas BioPharma) Price-to-Tangible-Book : 1.21 (As of May. 10, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Price-to-Tangible-Book?

As of today (2025-05-10), Zenas BioPharma's share price is $9.05. Zenas BioPharma's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $7.48. Hence, Zenas BioPharma's Price to Tangible Book Ratio of today is 1.21.

The historical rank and industry rank for Zenas BioPharma's Price-to-Tangible-Book or its related term are showing as below:

ZBIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1 Med: 1.1 Max: 1.21
Current: 1.21

During the past 3 years, Zenas BioPharma's highest Price to Tangible Book Ratio was 1.21. The lowest was 1.10. And the median was 1.10.

ZBIO's Price-to-Tangible-Book is ranked better than
75.85% of 1201 companies
in the Biotechnology industry
Industry Median: 2.58 vs ZBIO: 1.21

A closely related ratio is called PB Ratio. As of today, Zenas BioPharma's share price is $9.05. Zenas BioPharma's Book Value per Sharefor the quarter that ended in Dec. 2024 was $7.48. Hence, Zenas BioPharma's P/B Ratio of today is 1.21.

Zenas BioPharma Price-to-Tangible-Book Historical Data

The historical data trend for Zenas BioPharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Price-to-Tangible-Book Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Price-to-Tangible-Book

1.10

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial				-	-	-	1.97	1.10

Competitive Comparison of Zenas BioPharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Zenas BioPharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Zenas BioPharma Price-to-Tangible-Book Calculation

Zenas BioPharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	9.05	/	7.476
	=	1.21

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Zenas BioPharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.